Immune Design

We are a clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. Although we believe our approaches have broad potential across multiple therapeutic areas, we are focused in oncology and have engineered our technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells, or CTLs, to fight cancer. Our two primary product candidates, CMB305 and G100, utilize distinct immuno-oncology approaches that, we believe, address the shortcomings of existing therapies and have the potential to treat a broad patient population either as individual therapies or in combination with other mechanisms of action.

Type
Public
HQ
Seattle, US
Founded
2008
Employees
41 (est)

Immune Design Locations

Seattle, US
South San Francisco, US

Immune Design Metrics

Immune Design Summary

Founding Date

2008

Market capitalization

$185 M

Closing share price

$7.1

Immune Design Market Value History

Immune Design News

Immune Design Company Life

You may also be interested in